Regulatory perspective for quality evaluation of lipid nanoparticle-based mRNA vaccines in China
{{output}}
In recent years, urgent unmet medical needs due to the COVID-19 pandemic have accelerated the application of mRNA technology in vaccine development, leading to some of the first approvals of mRNA vaccines in human history by regulatory agencies around the worl... ...
